NuCana Compliant with All Nasdaq Continued Listing Criteria
NuCana (NASDAQ:NCNA) has announced its full compliance with all Nasdaq continued listing criteria, including the critical $1.00 minimum bid price requirement. The company has successfully resolved its previously disclosed Nasdaq listing concerns, with formal confirmation received on September 4, 2025.
Executive Chairman Andrew Kay highlighted that the company's current cash position, bolstered by ATM offering proceeds, is expected to fund operations into 2029. This extended runway will support multiple upcoming data readouts and key value-driving milestones in their cancer treatment development programs.
NuCana (NASDAQ:NCNA) ha annunciato di essere pienamente conforme a tutti i criteri di mantenimento della quotazione Nasdaq, incluso il requisito chiave del prezzo minimo per azione di $1,00. La società ha risolto con successo le questioni relative alla quotazione precedentemente comunicate, con conferma formale ricevuta il 4 settembre 2025.
Il Presidente Esecutivo Andrew Kay ha sottolineato che la posizione di cassa attuale della società, rafforzata dai proventi dell’offerta ATM, dovrebbe finanziare le operazioni fino al 2029. Questo prolungamento del runway sosterrà molteplici prossime comunicazioni di dati e tappe fondamentali che potranno creare valore nei programmi di sviluppo di terapie oncologiche.
NuCana (NASDAQ:NCNA) ha anunciado su plena conformidad con todos los criterios de mantenimiento de cotización de Nasdaq, incluido el requisito clave del precio mínimo por acción de $1.00. La compañía ha resuelto con éxito los asuntos de cotización previamente divulgados, con confirmación formal recibida el 4 de septiembre de 2025.
El Presidente Ejecutivo Andrew Kay señaló que la posición de caja actual de la compañía, reforzada por los ingresos de la oferta ATM, se espera que financie las operaciones hasta 2029. Esta extensión del runway apoyará múltiples próximas comunicaciones de datos y hitos clave que impulsarán el valor en sus programas de desarrollo de tratamientos contra el cáncer.
NuCana (NASDAQ:NCNA)는 최소 입찰가격 $1.00 요건을 포함한 모든 나스닥 상장 유지 기준을 완전히 충족했다고 발표했습니다. 회사는 이전에 공시한 상장 관련 문제들을 성공적으로 해결했으며, 2025년 9월 4일에 공식 확인을 받았습니다.
이사장(Executive Chairman) Andrew Kay는 ATM(At-the-Market) 공모 수익으로 강화된 현재 회사의 현금 위치가 2029년까지 운영 자금을 마련할 것이라고 강조했습니다. 이 연장된 자금 여유는 여러 차례의 데이터 공개와 암 치료 개발 프로그램의 핵심 가치 창출 이정표를 지원할 것입니다.
NuCana (NASDAQ:NCNA) a annoncé sa pleine conformité à tous les critères de maintien de la cotation Nasdaq, y compris l'exigence essentielle d'un cours minimum de $1.00. La société a résolu avec succès les préoccupations relatives à la cotation précédemment divulguées, confirmation formelle reçue le 4 septembre 2025.
Le Président exécutif Andrew Kay a souligné que la trésorerie actuelle de la société, renforcée par les produits de l'offre ATM, devrait financer les opérations jusqu'en 2029. Cette prolongation de la trésorerie soutiendra plusieurs prochaines publications de données et des étapes clés génératrices de valeur dans leurs programmes de développement de traitements contre le cancer.
NuCana (NASDAQ:NCNA) hat seine volle Einhaltung aller Nasdaq-Aufrechterhaltungskriterien, einschließlich der wichtigen Mindestgebotspreis-Anforderung von $1,00, bekannt gegeben. Das Unternehmen hat die zuvor offengelegten Nasdaq-Listing-Anliegen erfolgreich gelöst und am 4. September 2025 eine formelle Bestätigung erhalten.
Executive Chairman Andrew Kay betonte, dass die aktuelle Cash-Position des Unternehmens, gestützt durch Erlöse aus dem ATM-Angebot, voraussichtlich die Betriebsmittel bis ins Jahr 2029 finanzieren wird. Diese verlängerte Laufzeit wird mehrere bevorstehende Datenveröffentlichungen und zentrale werttreibende Meilensteine in ihren Programmen zur Entwicklung von Krebsbehandlungen unterstützen.
- Achieved full compliance with all Nasdaq listing requirements
- Cash runway extended into 2029 through successful ATM offering
- Multiple data readouts planned ahead
- Previous listing compliance issues required ATM offering, potentially diluting shareholders
Anticipated Cash Runway into 2029
EDINBURGH, United Kingdom, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced that it has received formal notification from The Nasdaq Stock Market on September 4, 2025 confirming that the Company is in compliance with all applicable Nasdaq continued listing criteria, including the
“As a result of the decisive steps we have taken, NuCana is now fully compliant with Nasdaq’s continued listing standards,” said Andrew Kay, NuCana’s Executive Chairman. “We anticipate our existing cash resources, which include proceeds raised to date via an ATM offering, will be sufficient to fund our planned operations into 2029 and through a number of key value-driving milestones.”
“We appreciate the opportunity provided by the Nasdaq Hearings Panel to demonstrate our full compliance,” added Mr. Kay. “We now have a strong cash position and with multiple data readouts ahead, we are well-positioned to deliver on our mission of improving treatment outcomes for patients with cancer.”
About NuCana
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy, and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-7738 and NUC-3373. NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373 is currently being evaluated in a Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Forward-Looking Statements
This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of the Company. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including NUC-7738 and NUC-3373; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical results; and the sufficiency of the Company’s current cash and cash equivalents to fund its planned operations into 2029. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to raise additional capital sufficient to fund our planned operations and the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.
For more information, please contact:
NuCana plc
Andrew Kay
Executive Chairman
+44 131-357-1111
info@nucana.com
ICR Healthcare
Chris Brinzey
+1 339-970-2843
Chris.Brinzey@ICRHealthcare.com
FAQ
Has NuCana (NCNA) regained Nasdaq compliance in 2025?
How long will NuCana's current cash runway last?
What are the next major milestones for NuCana (NCNA)?
What steps did NuCana take to maintain Nasdaq listing?
